COSMOS Pharmaceutical Corporation
CSMYF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,011 | $965 | $828 | $755 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Cost of Goods Sold | $798 | $777 | $659 | $604 |
| Gross Profit | $213 | $188 | $169 | $151 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $2 | $123 | $108 |
| Sales & Mktg Exp. | $0 | $2 | $2 | $2 |
| Other Operating Expenses | $173 | $155 | $3 | $3 |
| Operating Expenses | $173 | $157 | $139 | $122 |
| Operating Income | $40 | $32 | $30 | $30 |
| % Margin | 4% | 3.3% | 3.6% | 3.9% |
| Other Income/Exp. Net | $2 | $2 | $3 | $3 |
| Pre-Tax Income | $42 | $34 | $33 | $33 |
| Tax Expense | $11 | $9 | $9 | $10 |
| Net Income | $31 | $24 | $24 | $23 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS | 390.86 | 308.61 | 600.95 | 584.74 |
| % Growth | 26.7% | -48.6% | 2.8% | – |
| EPS Diluted | 390.86 | 308.61 | 600.95 | 584.74 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $22 | $20 | $17 | $15 |
| EBITDA | $65 | $54 | $50 | $48 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |